Last €12.75 EUR
Change Today +0.186 / 1.48%
Volume 0.0
AB3A On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:17 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (AB3A) Snapshot

Open
€12.45
Previous Close
€12.56
Day High
€12.79
Day Low
€12.44
52 Week High
04/24/14 - €28.44
52 Week Low
10/27/14 - €11.25
Market Cap
526.7M
Average Volume 10 Days
158.8
EPS TTM
--
Shares Outstanding
41.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAREPTA THERAPEUTICS INC (AB3A)

sarepta therapeutics inc (AB3A) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

146 Employees
Last Reported Date: 03/3/14
Founded in 1980

sarepta therapeutics inc (AB3A) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $457.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $377.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $376.9K
Senior Vice President of Technical Operations
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

sarepta therapeutics inc (AB3A) Key Developments

Sarepta Therapeutics, Inc. Initiates Dosing in Confirmatory Study of Eteplirsen

Sarepta Therapeutics, Inc. announced that it has initiated dosing in a confirmatory study of eteplirsen, the company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in ambulatory patients who meet specific criteria on their baseline 6-minute walk test score. This open-label study, 4658-301 (PROMOVI), designed to evaluate the efficacy and safety of eteplirsen in DMD patients over 48 weeks of dosing, will be conducted at approximately 39 sites across the United States and include up to 160 patients. The study will enroll 60-80 boys, aged 7-16 years with genotypes amenable to exon 51 skipping who will be treated with eteplirsen, while an additional 60-80 patients with genotypes not amenable to exon 51 skipping will serve as a concurrent control group. Patients enrolled in the treatment group of the study will receive once weekly intravenous infusions of 30 mg/kg of eteplirsen. Data will be collected across a number of efficacy and safety parameters, including dystrophin assessments and will be powered to show a benefit on the 6-minute walk test compared with the untreated DMD control group.

Sarepta Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

Sarepta Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the third quarter, the company reported revenue from grants and research contracts of $1.059 million, down from $4.168 million for the third quarter of 2013. The $3.1 million decrease was primarily due to decreases in revenue from the Company's government contracts. The government contract under which the Marburg drug candidate was being developed expired in July 2014 and the company is currently evaluating options to continue advancing its Marburg drug candidate and other infectious disease research and development efforts. Operating loss was $33.675 million against $24.933 million a year ago. Net loss was $29.226 million or $0.71 per basic and diluted share against $42.030 million or $1.24 per basic and diluted share a year ago. The decrease in net loss is primarily due to a favorable change of $21.4 million in gain (loss) on change in warrant valuation offset by an increase of $5.6 million in operating expenses and a decrease of $3.1 million in contract revenue. Non-GAAP net loss was $28.833 million or $0.70 per basic and diluted share against $21.329 million or $0.63 per basic and diluted share a year ago. The incremental loss of $7.5 million was primarily the result of increased general and administrative expenses as a result of corporate growth as well as a decrease in revenue from the company's government contracts. For the nine months, the company reported revenues from grants and research contracts of $9.730 million against $11.593 million a year ago. Operating loss was $89.067 million against $57.435 million a year ago. Net loss was $91.373 million or $2.31 per basic and diluted share against $103.165 million or $3.17 per basic and diluted share a year ago. Non-GAAP net loss was $71.005 million or $1.87 per basic and diluted share against $48.952 million or $1.50 per basic and diluted share a year ago. The company provided earnings guidance for the year 2014. In light of the recent FDA guidance for the eteplirsen NDA, the company has reduced planned expenditures for the remainder of the year, and now expects non-GAAP loss from operations to range from $110 million to $120 million, down from previous guidance of $135 million to $145 million. The company expects that its current financial position and prudent expense management will support the execution of its strategic business plan. The company cannot provide a reconciliation of this non-GAAP guidance to its relevant GAAP measure because full year loss from operations could include incremental expense related to stock compensation expense.

Sarepta Therapeutics, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 10:20 AM

Sarepta Therapeutics, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 10:20 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Christopher Nishan Garabedian, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €12.75 EUR +0.186

AB3A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,741 GBp +30.00
Baxter International Inc $72.44 USD +0.45
Gilead Sciences Inc $100.58 USD -0.01
Hemispherx Biopharma Inc $0.26 USD -0.007
SciClone Pharmaceuticals Inc $8.63 USD -0.05
View Industry Companies
 

Industry Analysis

AB3A

Industry Average

Valuation AB3A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.3x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit www.sareptatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.